Your browser doesn't support javascript.
loading
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules.
Harper, Jane; Adams, Katherine J; Bossi, Giovanna; Wright, Debbie E; Stacey, Andrea R; Bedke, Nicole; Martinez-Hague, Ruth; Blat, Dan; Humbert, Laure; Buchanan, Hazel; Le Provost, Gabrielle S; Donnellan, Zoe; Carreira, Ricardo J; Paston, Samantha J; Weigand, Luise U; Canestraro, Martina; Sanderson, Joseph P; Botta Gordon-Smith, Sophie; Lowe, Kate L; Rygiel, Karolina A; Powlesland, Alex S; Vuidepot, Annelise; Hassan, Namir J; Cameron, Brian J; Jakobsen, Bent K; Dukes, Joseph.
Afiliação
  • Harper J; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Adams KJ; Adaptimmune, Oxford, United Kingdom.
  • Bossi G; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Wright DE; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Stacey AR; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Bedke N; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Martinez-Hague R; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Blat D; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Humbert L; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Buchanan H; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Le Provost GS; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Donnellan Z; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Carreira RJ; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Paston SJ; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Weigand LU; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Canestraro M; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Sanderson JP; Adaptimmune, Oxford, United Kingdom.
  • Botta Gordon-Smith S; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Lowe KL; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Rygiel KA; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Powlesland AS; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Vuidepot A; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Hassan NJ; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Cameron BJ; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Jakobsen BK; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
  • Dukes J; Immunocore Ltd, Abingdon, Oxford, United Kingdom.
PLoS One ; 13(10): e0205491, 2018.
Article em En | MEDLINE | ID: mdl-30321203
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Ensaios de Seleção de Medicamentos Antitumorais / Proteínas / Anticorpos Biespecíficos / Anticorpos de Cadeia Única Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Ensaios de Seleção de Medicamentos Antitumorais / Proteínas / Anticorpos Biespecíficos / Anticorpos de Cadeia Única Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Reino Unido